Epigenetics and Neurotoxicity of Methamphetamine: An Active Killer During the Opioid Epidemic
A Part of SunCloud's CME/CEU Program of Events
The Facts About 2023’s Deadly Speedball: Fentanyl plus Methamphetamine
Methamphetamine use disorder (MUD) is a common neuropsychiatric disease that is associated with several short-term and long-term complications. These include cognitive deficits, memory impairments, and psychosis. There is presently no FDA-approved drug treatment for MUD. Dr. Cadet’s laboratory uses basic science approaches to develop better pharmacological therapy for these patients.
Learning Objectives:
To learn basic aspects of methamphetamine
Neurochemical effects
Behavioral effects
To learn the varied clinical presentations of methamphetamine use
Acute effects
Chronic effects
To learn the DSM criteria of methamphetamine use disorder
Compulsive use
Loss of control
Use despite adverse consequences
To learn about animal models of methamphetamine use disorder in rats
Behavioral effects of punishment (adverse consequences)
Jean Lud Cadet, M.D. is presently a NIH Tenured Senior Investigator and the Chief of the Molecular Neuropsychiatry Research Branch and of the Molecular Neuropsychiatry Section at the National Institutes of Health/National Institute on Drug Abuse (NIDA) intramural research program (IRP). Dr. Cadet attended medical school at the Columbia University College of Physicians and Surgeons. He subsequently did psychiatry residency at the Department of Psychiatry at
Columbia University and Neurology Residency at Mount Sinai Hospital in New York City. He did a post-residency fellowship at the NIMH and was an assistant professor of Neurology and Psychiatry at Columbia University before coming to NIDA IRP. Dr. Cadet has co-authored more than 500 papers, reviews, and book chapters on the molecular neurobiology of substance use disorders, cognitive aspects of cocaine and marijuana use disorders, clinical neurobiology of
schizophrenia and tardive dyskinesia, as well as on mechanisms involved in models of neurodegeneration including Parkinsonism. His work is very highly cited, with 29,691 citations and he presently has a H-index of 92. Presently, his laboratory studies the epigenetic mechanisms that potentially regulate stimulant and oxycodone-induced changes in the expression of genes in specific neuronal cells and brain regions within the reward pathways. Dr. Cadet has served on the Editorial Board of Synapse, is presently on the Editorial Board of Neurotoxicity Research, Current Neuropharmacology, International Journal of Neuropsychopharmacology, Scientific reports, and the Journal of Addictive Diseases. He is a reviewing editor for Scientific Reports and associate editor of
Frontier in Public Health. Dr. Cadet is also a member of the Society for Neuroscience, ASPET, National Medical Association, Black in Neuro, Neurotoxicity Society, AMHE (Association des Medecins Haitiens a L’ Etranger), Society of Haitian Neuroscientists (SHN). He has received several awards including the NIH Director’s Award, visiting professorships including the Grass
Foundation Lectureship, The Associated Medical Schools of NY for dedication and service to the promotion of Science and Health among minority youth, and the NIH Harvey J. Bullock Award.
Joint Accreditation Statement: In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Galen Mental Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Explaining SunCloud’s Integrated Model Why is an integrated treatment model
essential to successfully treating patients?
Dr. Kim Dennis, Co-Founder and Medical Director at SunCloud Health, discusses the vital role the integrated model (that she is pioneering at SunCloud Health) plays in the success of treating patients with co-occurring disorders and underlying trauma. How does SunCloud create an authentic culture of patient support?
Accreditations, Certifications & Licensing
The Joint Commission signifies that all people always experience the safest, highest quality, best-value health care across all settings with a devotion to patient safety. The Gold Seal, is a symbol to the community and patients we serve that SunCloud Health has placed an emphasis on quality of care.
